Notably, our study reveals that the EFNA1-SE signature is restricted to 7 of 24 cancer types, with a remarkably high prevalence (56%) in CC, underscoring the substantial heterogeneity of SE landscapes across different malignancies and individual patients. The gene discussed is EFNA1; the disease is cancer.